Ravi Goyal
Ravi Goyal
MD, PhD, MBA, FAHA
Contact
Ravi Goyal, MD, PhD, MBA, FAHA
Vice Chair of Research, OB/GYN · University of Arizona

Ravi Goyal, MD, PhD, MBA, FAHA

Tenured Professor · Department of Obstetrics and Gynecology · Chair of Research Strategic Plan Committee · Director of Resident Research

NIH-funded physician-scientist directing translational research portfolios at the intersection of maternal-fetal medicine, vascular biology, and developmental programming of health and disease.

University of Arizona College of Medicine BIO5 Institute UA Cancer Center SWEHSC (NIEHS P30)
$14M+
NIH funding as PI
55+
Peer-reviewed publications
FAHA
Fellow, American Heart Association
15+
AHA / NIH study sections
Research focus

Bench to bedside, across the lifespan.

My work focuses on the cellular and molecular mechanisms by which the in utero environment shapes lifelong health, with particular emphasis on vascular and cardiovascular adaptations.

Maternal-Fetal Medicine

Developmental Programming

How maternal stressors — hypoxia, undernutrition, vitamin D deficiency — shape fetal physiology and predispose offspring to adult cardiovascular and metabolic disease.

Vascular Biology

Cerebral & Pulmonary Arteries

Calcium signaling, receptor pharmacology, and gene expression changes in cerebral and pulmonary arterial smooth muscle across development and acclimatization.

Epigenetics

Renin-Angiotensin System Programming

Antenatal stress and methylation-mediated programming of the RAS in placental, lung, brain, and pancreatic tissues — with sex-dimorphic outcomes.

Computational Biology

Multiscale Models

Multiscale digital twins of endometrial hormone signaling and cell-state transitions, calibrated against published single-cell RNA-seq atlases.

Current roles

Affiliations.

UA

University of Arizona College of Medicine

Department of Obstetrics and Gynecology · Tucson, Arizona · 2023–Present

  • Vice Chair of Research, Department of Obstetrics and Gynecology
  • Tenured Professor, Department of Obstetrics and Gynecology
  • Chair, Research Strategic Plan Committee
  • Director, Resident Research and OB/GYN Journal Club
  • • Professor, Department of Physiology
  • • Professor, Physiological Sciences Graduate Interdisciplinary Program
  • • Member, Strategic Planning and Budget Advisory Committee (2023–2027)
University profile ↗
B5

BIO5 Institute · UA Cancer Center · SWEHSC

University of Arizona interdisciplinary centers

  • Professor, BIO5 Institute (2019–Present)
  • • Member, University of Arizona Cancer Center (2018–Present)
  • • Member, Southwest Environmental Health Sciences Center (NIEHS P30-funded) (2020–Present)
BIO5 profile ↗
AHA

American Heart Association · NIH Study Sections

Federal & professional service

  • Fellow, American Heart Association (FAHA), 2019
  • • AHA Study Section reviewer — 15+ review panels since 2009
  • • NIH ad hoc reviewer — 4+ committees since 2016
  • • Swiss National Science Foundation grant reviewer
  • • Editorial Board, Frontiers in Epigenomics · BioMed Central Journals
  • • Arizona Biomedical Research Center (ABRC) reviewer
EP

Epigenuity LLC

Scientific Founder · Tucson, AZ

Physician-scientist-founded research company developing decision-support software and diagnostic platforms across maternal health, oncology, and acute care. Six active programs including EndoTwin-W (computational digital twin) and PPHrisk (postpartum hemorrhage decision support, in market).

epigenuity.com ↗
Funded research

$14M+ in NIH funding as PI.

Sustained NIH funding across NICHD, NHLBI, NIEHS, and NIA, plus institutional pilot awards and study-section service.

Active awards
R01 · NICHD
PI
2023–2028 · $1.92M
R01HD109310 — Alpha1-Adrenergic Receptor Promoter Methylation in Cerebral Autoregulation
Examining cooperativity of H3K27Ac, H3K4Me3, and DNA methylation in regulating cerebral blood flow.
R03 · NICHD
PI
2023–2025 · $153K
R03HD108425 — Alpha-Adrenergic Methylation and Cerebral Autoregulation in Preterm Fetus
Mechanisms of alpha-adrenergic receptor expression and developmental DNA methylation.
R01 · NIDDK
Co-I
2022–2027 · $2.27M
R01DK084842 — Prevention of Placental Insufficiency Improves Beta-Cell Function
Oxygen/glucose replacement strategies in FGR fetuses · PI: Limesand SW.
R01 · NICHD
Co-I
2023–2027 · $2.64M
R01OD035553 — Reestablishing Muscle Growth in the Growth-Restricted Fetal Lamb
Oxygen/glucose replacement and skeletal muscle growth · PI: Limesand SW.
Pending applications · $20M+ requested
R01 · NHLBI (PI)
Mechanistic Insights into Fetal Growth Restriction and Cerebral Blood Flow
R01HD120889 · $3.77M · 2025–2030
R01 · NHLBI (PI)
B-Raf Kinase and Regulation of Placentation and Pregnancy
R01HL169384 · $3.06M · 2026–2031
R01 · NIA (PI)
Pectopexy as a Safer Alternative for Post-Hysterectomy Vault Prolapse
R01AG097478 · $3.77M · 2025–2030
PCORI (PI)
Sleep Interventions in Hypertensive Disorders of Pregnancy
PCORI-45579 · $7.00M · 2026–2031
Gates Foundation (PI)
sFlt1: Early Prediction and Therapy for Preeclampsia
$500K · 2026–2028
R01 · NIGMS (PI)
Diagnostic Center of Excellence for Recurrent Pregnancy Loss
2026–2029
Completed PI awards · selected highlights
R01 · NHLBI
Sympathetic Innervation & α1-AR Subtypes in Cerebral Artery
R01HL135786 · $1.98M · 2016–2021
P01 · NICHD
Cerebral Artery Alpha1 AR & PKC Regulatory Mechanisms
P01HD31226 · $7.86M · 2015–2020 (Loma Linda)
R56 · NHLBI
Raf Kinase & Epigenetic Regulation of Fetal Vascular Development
R56HL126778 · $395K · 2015–2017
R21 · NICHD
Role of LincRNA in Developmental Regulation of Angiogenesis
R21HD081283 · $434K · 2014–2016

Plus NIFA, NIH/NIEHS P30 pilot, UA institutional awards, and Bio5 Institute funding. AHA study section reviewer since 2009 (15+ panels). NIH ad hoc reviewer since 2016.

Selected publications

Peer-reviewed work.

55+ publications across maternal-fetal physiology, vascular biology, developmental epigenetics, and translational medicine. Selected highlights:

Full PubMed bibliography
55 publications · 2007–2023 · My NCBI
Translational ventures

From bench to product.

Founder of Epigenuity LLC and active programs translating research into deployable products.

Contact

Get in touch.

Open to research collaborations, advisory roles, speaking engagements, and partnership opportunities.